Aarhus University Seal / Aarhus Universitets segl

LifeTime and improving European healthcare through cell-based interceptive medicine

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Nikolaus Rajewsky, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, German Centre for Cardiovascular Research
  • ,
  • Geneviève Almouzni, Institut Curie
  • ,
  • Stanislaw A. Gorski, Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • ,
  • Stein Aerts, KU Leuven, VIB Center for Brain and Disease Research
  • ,
  • Ido Amit, Weizmann Institute of Science
  • ,
  • Michela G. Bertero, The Barcelona Institute of Science and Technology (BIST)
  • ,
  • Christoph Bock, Austrian Academy of Sciences, Medical University of Vienna, Ludwig Boltzmann Institute
  • ,
  • Annelien L. Bredenoord, University Medical Center Utrecht
  • ,
  • Giacomo Cavalli, Universite de Montpellier
  • ,
  • Susanna Chiocca, IRCCS Istituto Europeo di Oncologia - Milano
  • ,
  • Hans Clevers, Oncode Institute, Princess Maxima Center for Pediatric Oncology, Royal Netherlands Academy of Arts and Sciences, Amsterdam, University Medical Center Utrecht
  • ,
  • Bart De Strooper, KU Leuven, University College London, VIB Center for Brain and Disease Research
  • ,
  • Angelika Eggert, Berlin Institute of Health, Charité – Universitätsmedizin Berlin
  • ,
  • Jan Ellenberg, European Molecular Biology Laboratory
  • ,
  • Xosé M. Fernández, Institut Curie
  • ,
  • Marek Figlerowicz, Polish Academy of Sciences, Poznan University of Technology
  • ,
  • Susan M. Gasser, University of Basel, Friedrich Miescher Institute for Biomedical Research
  • ,
  • Norbert Hubner, Charité – Universitätsmedizin Berlin, Berlin Institute of Health, German Centre for Cardiovascular Research, Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • ,
  • Jørgen Kjems
  • Jürgen A. Knoblich, Austrian Academy of Sciences, Medical University of Vienna
  • ,
  • Grietje Krabbe, Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • ,
  • Peter Lichter, German Cancer Research Center
  • ,
  • Sten Linnarsson, Karolinska Institutet, Science for Life Laboratory
  • ,
  • Jean Christophe Marine, KU Leuven
  • ,
  • John C. Marioni, European Molecular Biology Laboratory, University of Cambridge, Wellcome Sanger Institute
  • ,
  • Marc A. Marti-Renom, The Barcelona Institute of Science and Technology (BIST), Centre for Genomic Regulation, Pompeu Fabra University, ICREA
  • ,
  • Mihai G. Netea, University of Bonn, Radboud University Medical Center
  • ,
  • Dörthe Nickel, Institut Curie
  • ,
  • Marcelo Nollmann, Universite de Montpellier
  • ,
  • Halina R. Novak, VIB Technology Watch
  • ,
  • Helen Parkinson, European Molecular Biology Laboratory
  • ,
  • Stefano Piccolo, FIRC Institute of Molecular Oncology, University of Padua School of Medicine
  • ,
  • Inês Pinheiro, Institut Curie
  • ,
  • Ana Pombo, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Humboldt University of Berlin
  • ,
  • Christian Popp, Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • ,
  • Wolf Reik, Wellcome Sanger Institute, Babraham Institute, University of Cambridge
  • ,
  • Sergio Roman-Roman, PSL Research University
  • ,
  • Philip Rosenstiel, Kiel University, University Hospital Schleswig-Holstein
  • ,
  • Joachim L. Schultze, University of Bonn, German Center for Neurodegenerative Diseases
  • ,
  • Oliver Stegle, European Molecular Biology Laboratory, Wellcome Sanger Institute, German Cancer Research Center
  • ,
  • Amos Tanay, Weizmann Institute of Science
  • ,
  • Giuseppe Testa, IRCCS Istituto Europeo di Oncologia - Milano, University of Milan, Human Technopole
  • ,
  • Dimitris Thanos, Academy of Athens
  • ,
  • Fabian J. Theis, Helmholtz Zentrum München - German Research Center for Environmental Health, Technical University of Munich
  • ,
  • Maria Elena Torres-Padilla
  • Alfonso Valencia, ICREA, Barcelona Supercomputing Center
  • ,
  • Céline Vallot, Institut Curie, PSL Research University
  • ,
  • Alexander van Oudenaarden, Oncode Institute, KNAW, Royal Netherlands Academy of Arts & Sciences, Utrecht University, Hubrecht Institute (KNAW), Hubrecht Inst, University Medical Center Utrecht
  • ,
  • Marie Vidal, Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • ,
  • Thierry Voet, KU Leuven, Wellcome Sanger Institute
  • ,
  • LifeTime Community Working Groups

Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.

Original languageEnglish
JournalNature
Volume587
Pages (from-to)377-386
Number of pages10
ISSN0028-0836
DOIs
Publication statusPublished - Nov 2020

See relations at Aarhus University Citationformats

ID: 201617049